Rein Therapeutics, Inc. (RNTX) Return on equity 2017–2025
Rein Therapeutics, Inc. (RNTX) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
-294.8%FY2025 · since FY2017: -47.3% → -294.8%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -294.8% | -179.2 pp |
| FY2024 | -115.6% | -99.6 pp |
| FY2023 | -16.0% | +130.7 pp |
| FY2022 | -146.7% | -87.2 pp |
| FY2021 | -59.6% | +165.1 pp |
| FY2020 | -224.7% | -41.7 pp |
| FY2019 | -183.0% | -22.1 pp |
| FY2018 | -161.0% | -113.7 pp |
| FY2017 | -47.3% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice